.png)
Antinuclear Antibody (ANA) Test Market By Product, Technique, Application and End User - Global Industry Analysis And Forecast To 2027
Published On : October 2018 Pages : 180 Category: Pharma & Healthcare Report Code : HC101460
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Antinuclear Antibody (ANA) Test Market By Product (Software & Services, Reagents & Assay Kits and Systems), Technique (Multiplex Assay, Immunofluorescence Assay and ELISA), Application (Scleroderma, Rheumatoid Arthritis, Sjogren’s Syndrome, Systemic Lupus Erythematosus and Other Applications) and End User (Physician Office Laboratories, Hospitals, Clinical Laboratories and Other End Users) - Global Industry Analysis And Forecast To 2027
Industry Outlook
The Antinuclear Antibody (ANA) are the group of autoantibodies that the immune system of a person produces. The test of antinuclear antibody searches for disorders related to autoimmune, for example, rheumatoid arthritis or lupus. The ANA test of blood is only one major player in a medical professional’s diagnosis for autoimmune disease, alongside a posting of your side effects, a physical exam, and different tests. The symptoms for which the doctor prefers the ANA test are tiredness, mild fever, weakness, light sensitivity, hair loss, pain in joint and/or muscle and feeling of tingling & numbness in the feet or hands. Therefore, the Antinuclear Antibody (ANA) Test Market is anticipated to expand and has tremendous scope during the forecast period. The global Antinuclear Antibody (ANA) Test Market anticipated to flourish in the future by growing at a significantly higher CAGR.
Market Segmentation
On the basis of Product the market is segmented into Software & Services, Reagents & Assay Kits and Systems. The Reagents & Assay Kits section is leading the market and is considered as the largest section in the market owing to increasing adoption of the product by research & clinical settings.
On the basis of Technique the market is segmented into Multiplex Assay, Immunofluorescence Assay and ELISA. The Immunofluorescence Assay section is leading the market due to rising adoption of the technique, the technique been more sensitive considered to other techniques, etc.
On the basis of Application the market is segmented into Scleroderma, Rheumatoid Arthritis, Sjogren’s Syndrome, Systemic Lupus Erythematosus and Other Applications. The section Rheumatoid Arthritis is leading the market owing to rising number of cases related to the disease.
On the basis of End User the market is segmented into Physician Office Laboratories, Hospitals, Clinical Laboratories and Other End Users. The Hospitals section is dominating the market owing to more number of the diagnostic examinations carried out here.
Regional Insights
The North American region is leading the global Antinuclear Antibody (ANA) Test Market followed by the European region owing to factors like well-developed healthcare sector, rising awareness amongst the patients, more developed tests present, rising adoption by the people, etc.
Antinuclear Antibody (ANA) Test Market, By Region
-
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.
- Trinity Biotech PLC
- Thermo Fisher Scientific Inc.
- Euroimmun AG
- Alere Inc.
- Erba Diagnostics
- Bio-Rad Laboratories.
- Inova Diagnostics
- Antibodies Inc.
- Zeus Scientific
- Immuno Concepts
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Antinuclear Antibody (ANA) Test Market, By Product, Estimates and Forecast, 2017-2027 ($Million)
o Software & Services
o Reagents & Assay Kits
o Systems
o Antinuclear Antibody (ANA) Test Market, By Technique, Estimates and Forecast, 2017-2027 ($Million)
o Multiplex Assay
o Immunofluorescence Assay
o ELISA
o Antinuclear Antibody (ANA) Test Market, By Application, Estimates and Forecast, 2017-2027 ($Million)
o Scleroderma
o Rheumatoid Arthritis
o Sjogren’s Syndrome
o Systemic Lupus Erythematosus
o Other Applications
o Antinuclear Antibody (ANA) Test Market, By End User, Estimates and Forecast, 2017-2027 ($Million)
o Physician Office Laboratories
o Hospitals
o Clinical Laboratories
o Other End Users
o Antinuclear Antibody (ANA) Test Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Antinuclear Antibody (ANA) Test Market , By Country
o U.S. Antinuclear Antibody (ANA) Test Market
o Canada Antinuclear Antibody (ANA) Test Market
o Mexico Antinuclear Antibody (ANA) Test Market
o Europe
§ Europe Antinuclear Antibody (ANA) Test Market , By Country
o Germany Antinuclear Antibody (ANA) Test Market
o UK Antinuclear Antibody (ANA) Test Market
o France Antinuclear Antibody (ANA) Test Market
o Russia Antinuclear Antibody (ANA) Test Market
o Italy Antinuclear Antibody (ANA) Test Market
o Rest of Europe Antinuclear Antibody (ANA) Test Market
o Asia-Pacific
§ Asia-Pacific Antinuclear Antibody (ANA) Test Market , By Country
o China Antinuclear Antibody (ANA) Test Market
o Japan Antinuclear Antibody (ANA) Test Market
o South Korea Antinuclear Antibody (ANA) Test Market
o India Antinuclear Antibody (ANA) Test Market
o Southeast Asia Antinuclear Antibody (ANA) Test Market
o Rest of Asia-Pacific Antinuclear Antibody (ANA) Test Market
o South America
§ South America Antinuclear Antibody (ANA) Test Market , By Country
o Brazil Antinuclear Antibody (ANA) Test Market
o Argentina Antinuclear Antibody (ANA) Test Market
o Columbia Antinuclear Antibody (ANA) Test Market
o Rest of South America Antinuclear Antibody (ANA) Test Market
o Middle East and Africa
§ Middle East and Africa Antinuclear Antibody (ANA) Test Market , By Country
o Saudi Arabia Antinuclear Antibody (ANA) Test Market
o UAE Antinuclear Antibody (ANA) Test Market
o Egypt Antinuclear Antibody (ANA) Test Market
o Nigeria Antinuclear Antibody (ANA) Test Market
o South Africa Antinuclear Antibody (ANA) Test Market
o Rest of MEA Antinuclear Antibody (ANA) Test Market
Table of Contents
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Antinuclear Antibody (ANA) Test Market, By Product
5.1. Introduction
5.2. Global Antinuclear Antibody (ANA) Test Revenue and Market Share by Product (2017-2027)
5.2.1. Global Antinuclear Antibody (ANA) Test Revenue and Revenue Share by Product (2017-2027)
5.3. Software & Services
5.3.1. Global Software & Services Revenue and Growth Rate (2017-2027)
5.4. Reagents & Assay Kits
5.4.1. Global Reagents & Assay Kits Revenue and Growth Rate (2017-2027)
5.5. Systems
5.5.1. Global Systems Revenue and Growth Rate (2017-2027)
6. Antinuclear Antibody (ANA) Test Market, By Technique
6.1. Introduction
6.2. Global Antinuclear Antibody (ANA) Test Revenue and Market Share by Technique (2017-2027)
6.2.1. Global Antinuclear Antibody (ANA) Test Revenue and Revenue Share by Technique (2017-2027)
6.3. Multiplex Assay
6.3.1. Global Multiplex Assay Revenue and Growth Rate (2017-2027)
6.4. Immunofluorescence Assay
6.4.1. Global Immunofluorescence Assay Revenue and Growth Rate (2017-2027)
6.5. ELISA
6.5.1. Global ELISA Revenue and Growth Rate (2017-2027)
7. Antinuclear Antibody (ANA) Test Market, By Application
7.1. Introduction
7.2. Global Antinuclear Antibody (ANA) Test Revenue and Market Share by Application (2017-2027)
7.2.1. Global Antinuclear Antibody (ANA) Test Revenue and Revenue Share by Application (2017-2027)
7.3. Scleroderma
7.3.1. Global Scleroderma Revenue and Growth Rate (2017-2027)
7.4. Rheumatoid Arthritis
7.4.1. Global Rheumatoid Arthritis Revenue and Growth Rate (2017-2027)
7.5. Sjogren’s Syndrome
7.5.1. Global Sjogren’s Syndrome Revenue and Growth Rate (2017-2027)
7.6. Systemic Lupus Erythematosus
7.6.1. Global Systemic Lupus Erythematosus Revenue and Growth Rate (2017-2027)
7.7. Other Applications
7.7.1. Global Other Applications Revenue and Growth Rate (2017-2027)
8. Antinuclear Antibody (ANA) Test Market, By End User
8.1. Introduction
8.2. Global Antinuclear Antibody (ANA) Test Revenue and Market Share by End User (2017-2027)
8.2.1. Global Antinuclear Antibody (ANA) Test Revenue and Revenue Share by End User (2017-2027)
8.3. Physician Office Laboratories
8.3.1. Global Physician Office Laboratories Revenue and Growth Rate (2017-2027)
8.4. Hospitals
8.4.1. Global Hospitals Revenue and Growth Rate (2017-2027)
8.5. Clinical Laboratories
8.5.1. Global Clinical Laboratories Revenue and Growth Rate (2017-2027)
8.6. Other End Users
8.6.1. Global Other End Users Revenue and Growth Rate (2017-2027)
9. Antinuclear Antibody (ANA) Test Market, By Region
9.1. Introduction
9.2. Global Antinuclear Antibody (ANA) Test Revenue and Market Share by Regions
9.2.1. Global Antinuclear Antibody (ANA) Test Revenue by Regions (2017-2027)
9.3. North America Antinuclear Antibody (ANA) Test by Countries
9.3.1. North America Antinuclear Antibody (ANA) Test Revenue and Growth Rate (2017-2027)
9.3.2. North America Antinuclear Antibody (ANA) Test Revenue (Million USD) by Countries (2017-2027)
9.3.3. United States
9.3.3.1. United States Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.3.4. Canada
9.3.4.1. Canada Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.3.5. Mexico
9.3.5.1. Mexico Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.4. Europe Antinuclear Antibody (ANA) Test by Countries
9.4.1. Europe Antinuclear Antibody (ANA) Test Revenue and Growth Rate (2017-2027)
9.4.2. Europe Antinuclear Antibody (ANA) Test Revenue (Million USD) by Countries (2017-2027)
9.4.3. Germany
9.4.3.1. Germany Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.4.4. France
9.4.4.1. France Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.4.5. UK
9.4.5.1. UK Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.4.6. Russia
9.4.6.1. Russia Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.4.7. Italy
9.4.7.1. Italy Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.4.8. Rest of Europe
9.4.8.1. Rest of Europe Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.5. Asia-Pacific Antinuclear Antibody (ANA) Test by Countries
9.5.1. Asia-Pacific Antinuclear Antibody (ANA) Test Revenue and Growth Rate (2017-2027)
9.5.2. Asia-Pacific Antinuclear Antibody (ANA) Test Revenue (Million USD) by Countries (2017-2027)
9.5.3. China
9.5.3.1. China Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.5.4. Japan
9.5.4.1. Japan Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.5.5. Korea
9.5.5.1. Korea Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.5.6. India
9.5.6.1. India Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.5.7. Southeast Asia
9.5.7.1. Southeast Asia Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.5.8. Rest of Asia-Pacific
9.5.8.1. Rest of Asia-Pacific Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.6. South America Antinuclear Antibody (ANA) Test by Countries
9.6.1. South America Antinuclear Antibody (ANA) Test Revenue and Growth Rate (2017-2027)
9.6.2. South America Antinuclear Antibody (ANA) Test Revenue (Million USD) by Countries (2017-2027)
9.6.3. Brazil
9.6.3.1. Brazil Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.6.4. Argentina
9.6.4.1. Argentina Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.6.5. Columbia
9.6.5.1. Columbia Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.6.6. Rest of South America
9.6.6.1. Rest of South America Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.7. Middle East and Africa Antinuclear Antibody (ANA) Test by Countries
9.7.1. Middle East and Africa Antinuclear Antibody (ANA) Test Revenue and Growth Rate (2017-2027)
9.7.2. Middle East and Africa Antinuclear Antibody (ANA) Test Revenue (Million USD) by Countries (2017-2027)
9.7.3. Saudi Arabia
9.7.3.1. Saudi Arabia Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.7.4. United Arab Emirates
9.7.4.1. United Arab Emirates Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.7.5. Egypt
9.7.5.1. Egypt Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.7.6. Nigeria
9.7.6.1. Nigeria Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.7.7. South Africa
9.7.7.1. South Africa Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.7.8. Turkey
9.7.8.1. Turkey Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
9.7.9. Rest of Middle East and Africa
9.7.9.1. Rest of Middle East and Africa Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
10. Company Profiles
10.1. Trinity Biotech PLC
10.1.1. Business Overview
10.1.2. Service Portfolio
10.1.3. Strategic Developments
10.1.4. Revenue and Market Share
10.2. Thermo Fisher Scientific Inc.
10.2.1. Business Overview
10.2.2. Service Portfolio
10.2.3. Strategic Developments
10.2.4. Revenue and Market Share
10.3. Euroimmun AG
10.3.1. Business Overview
10.3.2. Service Portfolio
10.3.3. Strategic Developments
10.3.4. Revenue and Market Share
10.4. Alere Inc.
10.4.1. Business Overview
10.4.2. Service Portfolio
10.4.3. Strategic Developments
10.4.4. Revenue and Market Share
10.5. Erba Diagnostics
10.5.1. Business Overview
10.5.2. Service Portfolio
10.5.3. Strategic Developments
10.5.4. Revenue and Market Share
10.6. Bio-Rad Laboratories.
10.6.1. Business Overview
10.6.2. Service Portfolio
10.6.3. Strategic Developments
10.6.4. Revenue and Market Share
10.7. Inova Diagnostics
10.7.1. Business Overview
10.7.2. Service Portfolio
10.7.3. Strategic Developments
10.7.4. Revenue and Market Share
10.8. Antibodies Inc.
10.8.1. Business Overview
10.8.2. Service Portfolio
10.8.3. Strategic Developments
10.8.4. Revenue and Market Share
10.9. Zeus Scientific
10.9.1. Business Overview
10.9.2. Service Portfolio
10.9.3. Strategic Developments
10.9.4. Revenue and Market Share
10.10. Immuno Concepts
10.10.1. Business Overview
10.10.2. Service Portfolio
10.10.3. Strategic Developments
10.10.4. Revenue and Market Share
11. Global Antinuclear Antibody (ANA) Test Market Competition, by Manufacturer
11.1. Global Antinuclear Antibody (ANA) Test Revenue and Market Share by Manufacturer (2017-2017)
11.2. Global Antinuclear Antibody (ANA) Test Price By Region (2017-2017)
11.3. Top 5 Antinuclear Antibody (ANA) Test Manufacturer Market Share
11.4. Market Competition Trend
12. Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.1. Global Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2027)
12.2. Antinuclear Antibody (ANA) Test Market Forecast by Regions (2017-2027)
12.2.1. North America Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.1.1. United States Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.1.2. Canada Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.1.3. Mexico Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.2. Europe Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.2.1. Germany Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.2.2. France Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.2.3. UK Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.2.4. Russia Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.2.5. Italy Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.2.6. Rest of Europe Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.3. Asia-Pacific Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.3.1. China Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.3.2. Japan Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.3.3. Korea Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.3.4. India Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.3.5. Southeast Asia Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.3.6. Rest of Asia-Pacific Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.4. South America Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.4.1. Brazil Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.4.2. Argentina Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.4.3. Columbia Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.4.4. Rest of South America Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.5. Middle East and Africa Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.5.1. Saudi Arabia Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.5.2. United Arab Emirates Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.5.3. Egypt Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.5.4. Nigeria Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.5.5. South Africa Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.5.6. Turkey Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.2.5.7. Rest of Middle East and Africa Antinuclear Antibody (ANA) Test Market Forecast (2017-2027)
12.3. Antinuclear Antibody (ANA) Test Market Forecast by Product (2017-2027)
12.3.1. Antinuclear Antibody (ANA) Test Forecast by Product (2017-2027)
12.3.2. Antinuclear Antibody (ANA) Test Market Share Forecast by Product (2017-2027)
12.4. Antinuclear Antibody (ANA) Test Market Forecast by Technique (2017-2027)
12.4.1. Antinuclear Antibody (ANA) Test Forecast by Technique (2017-2027)
12.4.2. Antinuclear Antibody (ANA) Test Market Share Forecast by Technique (2017-2027)
12.5. Antinuclear Antibody (ANA) Test Market Forecast by Application (2017-2027)
12.5.1. Antinuclear Antibody (ANA) Test Forecast by Application (2017-2027)
12.5.2. Antinuclear Antibody (ANA) Test Market Share Forecast by Application (2017-2027)
12.6. Antinuclear Antibody (ANA) Test Market Forecast by End User (2017-2027)
12.6.1. Antinuclear Antibody (ANA) Test Forecast by End User (2017-2027)
12.6.2. Antinuclear Antibody (ANA) Test Market Share Forecast by End User (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Antinuclear Antibody (ANA) Test Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Antinuclear Antibody (ANA) Test Revenue and Revenue Share by Product (2017-2018)
Figure Global Software & Services Revenue and Growth Rate (2017-2018)
Figure Global Reagents & Assay Kits Revenue and Growth Rate (2017-2018)
Figure Global Systems Revenue and Growth Rate (2017-2018)
Table Global Antinuclear Antibody (ANA) Test Revenue and Revenue Share by Technique (2017-2018)
Figure Global Multiplex Assay Revenue and Growth Rate (2017-2018)
Figure Global Immunofluorescence Assay Revenue and Growth Rate (2017-2018)
Figure Global ELISA Revenue and Growth Rate (2017-2018)
Table Global Antinuclear Antibody (ANA) Test Revenue and Revenue Share by Application (2017-2018)
Figure Global Scleroderma Revenue and Growth Rate (2017-2018)
Figure Global Rheumatoid Arthritis Revenue and Growth Rate (2017-2018)
Figure Global Sjogren’s Syndrome Revenue and Growth Rate (2017-2018)
Figure Global Systemic Lupus Erythematosus Revenue and Growth Rate (2017-2018)
Figure Global Other Applications Revenue and Growth Rate (2017-2018)
Table Global Antinuclear Antibody (ANA) Test Revenue and Revenue Share by End User (2017-2018)
Figure Global Physician Office Laboratories Revenue and Growth Rate (2017-2018)
Figure Global Hospitals Revenue and Growth Rate (2017-2018)
Figure Global Clinical Laboratories Revenue and Growth Rate (2017-2018)
Figure Global Other End Users Revenue and Growth Rate (2017-2018)
Table Global Antinuclear Antibody (ANA) Test Revenue by Regions (2017-2018)
Figure North America Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure North America Antinuclear Antibody (ANA) Test Revenue and Growth Rate (2017-2018)
Figure North America Antinuclear Antibody (ANA) Test by Countries (2017-2018)
Figure North America Antinuclear Antibody (ANA) Test Revenue (Million USD) by Countries (2017-2018)
Figure United States Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure United States Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Canada Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Mexico Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Europe Antinuclear Antibody (ANA) Test Revenue and Growth Rate (2017-2018)
Figure Europe Antinuclear Antibody (ANA) Test by Countries (2017-2018)
Figure Europe Antinuclear Antibody (ANA) Test Revenue (Million USD) by Countries (2017-2018)
Figure Germany Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Germany Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure France Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure UK Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Russia Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Italy Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Rest of Europe Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Asia-Pacific Antinuclear Antibody (ANA) Test Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Antinuclear Antibody (ANA) Test by Countries (2017-2018)
Figure Asia-Pacific Antinuclear Antibody (ANA) Test Revenue (Million USD) by Countries (2017-2018)
Figure China Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure China Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Japan Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Korea Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure India Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Southeast Asia Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure South America Antinuclear Antibody (ANA) Test Revenue and Growth Rate (2017-2018)
Figure South America Antinuclear Antibody (ANA) Test by Countries (2017-2018)
Figure South America Antinuclear Antibody (ANA) Test Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Brazil Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Argentina Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Columbia Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Rest of South America Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Middle East and Africa Antinuclear Antibody (ANA) Test Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Antinuclear Antibody (ANA) Test by Countries (2017-2018)
Figure Middle East and Africa Antinuclear Antibody (ANA) Test Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Saudi Arabia Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure United Arab Emirates Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Egypt Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Nigeria Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure South Africa Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Turkey Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Antinuclear Antibody (ANA) Test Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2017-2018)
Table Trinity Biotech PLC Antinuclear Antibody (ANA) Test Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Thermo Fisher Scientific Inc. Antinuclear Antibody (ANA) Test Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Euroimmun AG Antinuclear Antibody (ANA) Test Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Alere Inc. Antinuclear Antibody (ANA) Test Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Erba Diagnostics Antinuclear Antibody (ANA) Test Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bio-Rad Laboratories. Antinuclear Antibody (ANA) Test Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Inova Diagnostics Antinuclear Antibody (ANA) Test Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Antibodies Inc. Antinuclear Antibody (ANA) Test Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Zeus Scientific Antinuclear Antibody (ANA) Test Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Immuno Concepts Antinuclear Antibody (ANA) Test Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Antinuclear Antibody (ANA) Test Market Share by Manufacturer
Figure Global Antinuclear Antibody (ANA) Test Revenue and Market Share by Manufacturer
Table Global Antinuclear Antibody (ANA) Test Price by Region (2017-2017)
Figure Top 5 Antinuclear Antibody (ANA) Test Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Antinuclear Antibody (ANA) Test Revenue (Millions USD) and Growth Rate (2018-2025)
Table Antinuclear Antibody (ANA) Test Market Forecast by Regions (2018-2025)
Figure North America Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure United States Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Canada Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Mexico Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Europe Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Germany Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure France Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure UK Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Russia Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Italy Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Rest of Europe Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Asia-Pacific Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure China Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Japan Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Korea Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure India Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Southeast Asia Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure South America Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Brazil Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Argentina Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Columbia Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Rest of South America Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Middle East and Africa Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Saudi Arabia Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure United Arab Emirates Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Egypt Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Nigeria Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure South Africa Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Turkey Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Antinuclear Antibody (ANA) Test Market Forecast (2018-2025)
Figure Global Antinuclear Antibody (ANA) Test Forecast by Product (2018-2025)
Figure Global Antinuclear Antibody (ANA) Test Market Share Forecast by Product (2018-2025)
Figure Global Antinuclear Antibody (ANA) Test Forecast by Product (2018-2025)
Figure Global Antinuclear Antibody (ANA) Test Forecast by Technique (2018-2025)
Figure Global Antinuclear Antibody (ANA) Test Market Share Forecast by Technique (2018-2025)
Figure Global Antinuclear Antibody (ANA) Test Forecast by Technique (2018-2025)
Figure Global Antinuclear Antibody (ANA) Test Forecast by Application (2018-2025)
Figure Global Antinuclear Antibody (ANA) Test Market Share Forecast by Application (2018-2025)
Figure Global Antinuclear Antibody (ANA) Test Forecast by Application (2018-2025)
Figure Global Antinuclear Antibody (ANA) Test Forecast by End User (2018-2025)
Figure Global Antinuclear Antibody (ANA) Test Market Share Forecast by End User (2018-2025)
Figure Global Antinuclear Antibody (ANA) Test Forecast by End User (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|